by Current Scenario of Global Troponin Industry
The Global Troponin marker was valued at US XX Million in 2017 and is projected to reach US XX Million by 2025, at a CAGR of XX% during the forecast period from 2018 to 2025. Troponins are regulatory proteins that bind to actin in muscle fibers. They play a key role in muscle contraction in skeletal and cardiac muscle. Measurement of cardiac troponins is important for the diagnosis and risk stratification of patients with suspected acute myocardial infarction. The two cardiac-specific troponin isoforms are called troponin T (TnT) and troponin I (TnI).
Rise in Cardiovascular diseases driving the market growth
The increasing prevalence of cardiovascular diseases such as myocardial infarction, unstable angina, and heart failure across the globe is the major factor contributing to the growth of the Global Troponin. As per the World Health Organization (WHO), cardiovascular diseases accounted for an estimated 17.9 million deaths globally in 2016, representing 31% of all global deaths. It is also reported that over 75% of these deaths take place in low- and middle-income countries. Early detection of cardiac injury plays a vital role in the management of patients with acute coronary syndrome. Measurement of cardiac troponins aids in quick diagnosis and risk stratification of patients presenting with symptoms of acute coronary syndrome. Therefore, the increasing burden of cardiovascular diseases will augment the demand for troponin tests globally.
Innovation in Assay Systems and technology adoption
Ongoing innovation and technological advancements in troponin assays have significantly improved the diagnostic capabilities for detection of minor increases in troponin levels in blood after cardiac injury. High-sensitivity troponin assays enable measurement of troponin levels well below the 99th percentile of the normal reference range. These assays detect subtle changes in cardiac troponin levels within 3-4 hours after the initial symptoms in patients with non-ST elevation myocardial infarction. Adoption of high sensitivity troponin testing across major markets is anticipated to drive the market growth during the forecast period. Various analytical advancements such as minimized sample volume requirement, faster turnaround time, and automation of analysis using immunochemistry analyzers offer compelling advantages over conventional troponin assays.
Regional Analysis of Global Troponin Industry
North America is currently dominating the global troponin market owing to the rising geriatric population, developing healthcare infrastructure, and presence of key market players in the region. Favorable reimbursement policies for cardiac tests in the U.S. also contribute to the large share of this regional market. Europe holds the second largest revenue share due to the increasing adoption of point-of-care testing and focus of European governments on early diagnosis and management of cardiovascular conditions. Asia Pacific market is projected to witness the highest growth over the forecast period majorly driven by growing healthcare expenditure, rising awareness regarding cardiovascular health, and improving access to diagnostic services in developing countries. Rapid economic growth in India and China are expected to provide significant opportunities for market expansion in Asia Pacific during next few years.
Key Market Players
The leading companies operating in the global troponin market include Roche Diagnostics, Abbott Laboratories, Siemens Healthcare GmbH, Beckman Coulter, Inc., and Randox Laboratories Ltd. Major players are focusing on new product launches, acquisitions, regulatory approvals, and geographical expansions to consolidate their market presence. For instance, in October 2017, Roche Diagnostics received FDA approval for its ELECSYS Troponin T Gen 5 STAT assay to rule out suspected myocardial infarction in patients presenting chest pain symptoms. In March 2017, Abbott Laboratories received FDA clearance for its high sensitivity troponin-I blood test to diagnose heart attack. Such regulatory approvals and new product launches allow these companies to strengthen their position as key innovators in the global troponin testing market.
Future Projections for Global Troponin Market
The future projections for global troponin market are quite encouraging driven by increasing awareness regarding early diagnosis of cardiovascular diseases. Ongoing technological developments and analytical advancements in cardiac troponin assays are anticipated to boost the market growth. It is expected that these factors will increase penetration of high sensitivity troponin assays to major healthcare facilities across the globe.
Introduction of novel biomarkers in combination with troponin testing and strategic alliances between market players and healthcare providers will provide new opportunities for revenue generation. However, availability of alternative markers with better sensitivity and specificity during initial hours of myocardial injury symptoms may restrain the demand for conventional troponin tests to some extent. On the whole, rising prevalence of heart diseases and growing focus on development of robust healthcare infrastructure in emerging nations will continue to drive the global troponin market during next five years.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
